Related Experiment Videos
Insights
Esophageal endosclerosis effectively treated esophageal variceal hemorrhage in children. This sclerotherapy method obliterated varices, preventing recurrence in most patients, offering a safe treatment for this condition.
Area of Science:
- Pediatric Gastroenterology
- Hepatology
- Endoscopic Interventions
Background:
- Esophageal variceal hemorrhage is a serious complication in children with portal hypertension.
- Portal vein thrombosis and biliary atresia are common underlying causes in pediatric populations.
- Effective treatment is crucial to prevent life-threatening bleeding episodes.
Purpose of the Study:
- To evaluate the efficacy and safety of esophageal endosclerosis for treating esophageal variceal hemorrhage in pediatric patients.
- To assess the long-term outcomes and recurrence rates following endosclerosis therapy.
- To analyze the complications associated with esophageal endosclerosis in this cohort.
Main Methods:
- A consecutive series of 25 pediatric patients with esophageal variceal hemorrhage underwent esophageal endosclerosis.
- Treatment involved direct injection of esophageal varices with a sclerosing agent, repeated until obliteration.
- Patients were followed for 9 months to 6 years post-therapy.
Main Results:
- Twenty-one of 25 patients completed therapy, with varices successfully obliterated.
- Recurrent esophageal variceal hemorrhage was not observed during the follow-up period.
- One treatment-related death occurred; other complications were minor.
Conclusions:
- Esophageal endosclerosis is an effective and generally safe treatment for esophageal variceal hemorrhage in children.
- The procedure leads to successful obliteration of varices and prevents recurrence.
- Long-term follow-up indicates a favorable outcome with minimal complications.
Abstract:
During the past 6 years, 25 consecutive patients with esophageal variceal hemorrhage were treated by esophageal endosclerosis (direct injection of varices with a sclerosing agent). The primary disease in the 25 children was portal vein thrombosis (11 patients), biliary atresia (nine patients), and hepatic cirrhosis from cystic fibrosis (three patients), alpha 1-antitrypsin deficiency (one patient), and neonatal hepatitis (one patient). Thirteen patients were treated during acute, major variceal hemorrhage. Esophageal endosclerosis was repeated at regular intervals until all esophageal varices were obliterated. Twenty-one patients completed therapy. Four patients died: one of a complication of therapy and three of the primary disease. Other than the one death, complications were minor. Recurrent esophageal variceal hemorrhage has not been encountered in follow-up from 9 months to 6 years after completion of therapy.